capmatinib hydrochloride

{
  "id": "MLC-T-ONC-001393",
  "term": "capmatinib hydrochloride",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with non-small cell lung cancer that has spread and has a certain mutation (change) in the MET gene. It is also being studied in the treatment of other types of cancer. Capmatinib hydrochloride blocks a protein made by the MET gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Tabrecta.",
    "The hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."
  ],
  "synonyms": [
    "Tabrecta"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/capmatinib-hydrochloride/"
}